Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994291 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT01994291 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 199 participants.
The verdict
NCT01994291, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema. The current treatment option for these subjects is an injection directly into the eye, while this CCR2/5 antagonist would be an oral drug which has the potential to be just as effective. This CCR2/5 antagonist also has a broader anti-inflammatory potential and might be able to provide an alternative mechanism to treat Diabetic Macular Edema.
Interventions
- DRUG Placebo
- DRUG Ranibizumab
- DRUG PF-04634817
- DRUG Masked Sham Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994291
The ClinicalTrials.gov registry entry for NCT01994291 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01994291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01994291 about?
NCT01994291 is a clinical study titled "A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema". The study hypothesis under test is that administration of the CCR2/5 antagonist has the potential to be as effective as the current treatment options for subjects with diabetic macular edema. The current treatment option for these subjects is an injection directly into the eye, while this CCR2/5 ant...
What is the current status of trial NCT01994291?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2013-11. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01994291?
The interventions under investigation include: Placebo (DRUG), Ranibizumab (DRUG), PF-04634817 (DRUG), Masked Sham Therapy (DRUG).
Who is sponsoring clinical trial NCT01994291?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.